Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (04/04/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Benign Tumors

Added Topical beta-blocker therapy as a new subsection.

Added Ge et al. as reference 60 and level of evidence 3iiDiv.

Added text to state that transplantation is considered only for patients with severe diffuse lesions who have multisystem organ failure and when there is insufficient time for effective pharmacologic therapy.

Intermediate Tumors (Locally Aggressive)

Added text to state that a single case report of a child with kaposiform hemangioendothelioma who developed recurrence of pain and fibrosis years after initial therapy was treated with sirolimus for 26 months; the patient's contracture and range of motion improved, the lesion shrank, and the child was well 2 years later (cited Oza et al. as reference 19).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary